[Cisplatin-Vepeside versus Endoxan-Vepeside in the treatment of small cell bronchial cancer. A randomized study].
Within the framework of a multi-centre prospective randomised therapeutic trial, 150 patients with small-cell lung cancer (SCLC) were treated with cisplatin/vepesid and endoxan/vepesid. The aim of the study was to establish whether cisplatin--which although effective is commonly associated with adverse effects--can be replaced by endoxan. The sequence of treatment was oriented to the stage and course of the tumour disease. In the event of a treatment failure, cross-over to the alternative combination was effected. In terms of remission rates, the combination cisplatin/vepesid proved to be more effective than endoxan/vepesid, in particular in the case of patients with extensive disease. With respect to duration of remission and survival duration, however, no significant differences were to be seen.
Heckmayr
M
M
Pneumologisch-onkologische Abteilung, Krankenhaus-Grosshansdorf.
Gatzemeier
U
U
Hossfeld
D K
DK
Koschel
G
G
Thies
F
F
Zschaber
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic
D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin
Cisplatin-Vepesid versus Endoxan-Vepesid in der Behandlung kleinzelliger Bronchialkarzinome. Eine randomisierte Studie.